Based on the molecular platform, Fangke Bio has successively carried out library sequencing, transcriptome sequencing (RNA-Seq), RNA immunoprecipitation sequencing (RIP seq), chromatin immunoprecipitation sequencing (ChIP-seq), single-cell transcriptome sequencing (Smart sequencing) and PCR product library sequencing services. The library is built and sequenced for qualified samples provided by partners, or the qualified library provided by partners is directly sequenced to produce high-quality sequencing data for customers to perform bioinformatics analysis. In addition, Fangke Bio has successively cooperated with many scientific research institutes, and the jointly developed Mycobacterium leprae nucleic acid detection kit and HLA-B*1301 gene detection kit have obtained CE certification.

Fangke Bio can carry out immunohistochemistry and ELISA testing services based on the immune platform. In addition, Fangke Bio cooperates with many scientific research institutes to carry out the research and development of companion diagnostic reagents. Among them, the jointly developed BP180&BP230 antibody detection kit improves the accuracy of predicting the side effects of tumor immunotherapy; the jointly developed MDA5 antibody detection kit, TIF1γ antibody detection kit and Jo-1 antibody detection kit provide solutions for predicting dermatomyositis/polydermatomyositis. In addition, Fangke Bio will further promote the development of Mycobacterium tuberculosis-specific cellular immune response detection kits and Dsg1&Dsg3 antibody detection kits, and R&D and services go hand in hand.